Visterra doses first patient in phase IIa trial for VIS410 for Influenza A
Visterra, a clinical-stage biopharmaceutical company, has announced that the first patient was dosed in a phase IIa clinical trial of VIS410, a monoclonal antibody in development for the treatment of hospitalized patients with influenza A, regardless of the viral strain.
This global phase IIa clinical trial is being conducted in approximately 150 ambulatory patients diagnosed with influenza A. Patients in the phase IIa clinical trial will be randomized into one of three arms to receive either 2000mg of VIS410, 4000mg of VIS410 or placebo. The primary endpoint of the study is safety and tolerability and secondary endpoints include clinical symptoms of influenza, virology and pharmacokinetics of VIS410.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201500018C.